

Contents

Section 1 Operational Developments in Chemistry

Chapter 1 The Use of Polymer-Assisted Solution-Phase Synthesis and Automation for the High-Throughput Preparation of Biologically Active Compounds	3
<i>Steven V. Ley, Mark Ladlow and Emma Vickerstaffe</i>	
1 Introduction	3
2 PASP Synthesis Approaches to Biologically Active Compounds	7
2.1 Applications to the Synthesis of Commercial Drug Molecules	7
2.2 Applications of PASP to the Synthesis of Biologically Active Natural Products	10
2.3 PASP Synthesis in the Library Production of Biologically Active Small Molecules	12
3 Automated PASP Synthesis of Biologically Active Molecules	19
3.1 Stepwise Automation of PASP Synthesis in Batch Mode	19
3.2 Fully Automated PASP Synthesis of Drug-Like Molecules in Batch Mode	21
3.3 Flow Chemistry and Automation in the Synthesis of Drug-Like Molecules	23
4 Conclusion	28
References	28
Chapter 2 Accelerated Chemistry: Microwave, Sonochemical, and Fluorous Phase Techniques	33
<i>Kristofer Olofsson, Peter Nilsson and Mats Larhed</i>	
1 Introduction	33

2	Microwave Enhanced Chemistry	34
2.1	General	34
2.2	Applications in Medicinal Chemistry	35
2.3	Applications in Solid-Phase Chemistry	37
3	Sonochemistry as a Means to Accelerate Synthesis	37
3.1	General	37
3.2	Organometallic Sonochemistry	38
3.3	Heterocyclic and Pericyclic Chemistry	38
3.4	Applications in Medicinal Chemistry	39
4	Fluorous Phase Techniques	40
4.1	General	40
4.2	Reagents, Linkers, and Scavengers	42
4.3	Fluorous Protecting Groups	44
4.4	Fluorous Mixture Synthesis	44
4.5	Peptides and Oligosaccharides	45
4.6	Fluorous Applications in High-Throughput Chemistry	46
4.7	Microwave-Enhanced Fluorous Chemistry	46
5	Conclusion	48
	Acknowledgements	48
	References	48

**Section 2 Conceptual Advances in Synthesis:
“Prospecting” – Design of Discovery
Libraries and the Search for Hits**

Chapter 3	Biosynthesis of “Unnatural” Natural Products	57
	<i>Yi Tang and Chaitan Khosla</i>	
1	Introduction	57
1.1	Polyketide Assembly	58
1.2	Three Major Classes of Polyketide Synthases	60
1.3	Methods for Engineered Biosynthesis	60
2	Type I Polyketide Synthases	61
2.1	Modular Architecture	61
2.2	The Erythromycin Synthase	63
2.3	Engineered Biosynthesis of Multimodular PKS Products	64
2.3.1	Domain Engineering	64
2.3.2	Module Engineering	66
2.3.3	Primer Unit Engineering and Precursor-Directed Biosynthesis	68
2.4	Multimodular PKSs that Exhibit Special Features	70
2.5	Fungal Type I PKSs	70

<i>Contents</i>	xiii
3 Type II Polyketide Synthases	72
3.1 Dissociated Architecture	72
3.2 Combinatorial Biosynthesis of Type II Polyketides	75
3.2.1 Chain-Length Variations	76
3.2.2 Mix and Match of Tailoring Enzymes	76
3.2.3 Primer Unit Modifications	78
3.2.4 Reshuffling of Downstream Tailoring Enzymes	80
4 Type III Polyketide Synthase	81
4.1 Type III PKS Consists of a Homodimeric Ketosynthase	81
4.2 Engineered Biosynthesis of Type III Polyketides	84
5 Conclusions	85
Acknowledgments	86
References	86

Chapter 4 Combinatorial Synthetic Design: The Balance of Novelty and Familiarity	91
<i>A. Ganesan</i>	
1 Biological Macromolecules – Strength in Numbers	91
1.1 Congruence between Biological and Chemical Space	93
1.2 The Libraries are Exhaustive within the Defined Boundaries	93
1.3 Highly Optimized Synthesis Procedures were Available	94
2 Oligomer Synthesis – Improving on Mother Nature	94
3 Random, Discovery, or Prospecting Libraries – the Quest for the Universal Scaffold	96
4 Privileged Scaffolds – Look Where the Light is Brightest	96
5 The Decoration or Synthesis of Novel Scaffolds – Aid for the Underprivileged	97
6 Target Class Libraries – Diversity with a Purpose	100
7 Peptide and Nucleotide Libraries Redux	101
8 Lead Discovery or Drug Discovery – Size does Matter	102
9 Natural Product Scaffolds for Combinatorial Chemistry – Why Reinvent the Wheel?	103
10 From Natural Products to Natural Product-Like Libraries – Hubris or Progress?	104

11	Lead Discovery and Combinatorial Chemistry – What have We Learned?	105
11.1	The Drug-Discovery Process cannot be Simplified to a Single Blueprint	106
11.2	Combinatorial Chemistry is an Extremely Powerful Technology	106
11.3	Combinatorial Chemistry is at its Best in Lead Optimization	107
11.4	Combinatorial Chemistry is about Making the Compounds that Fit Your Needs, not How They are Made	107
	References	107
Chapter 5	Compound Collections: Acquisition, Annotation, and Access	112
	<i>Reg Richardson</i>	
1	Introduction	112
2	Commercial Offerings	113
3	Companies Providing Non-Proprietary, Non-Parallel Synthesised Libraries (Shared-Pool/‘Collected Collections’)	115
4	Companies Providing In-House Designed, Parallel Synthesised Libraries	117
5	Compound Selection and Database Filtering	119
6	Sub-structure Similarity/Dissimilarity	119
7	Pharmacophore Analysis	120
8	Annotation	124
9	Lipinski Rule-of-Five (LRoF)	126
10	Topological Polar Surface Area (tPSA) and Blood–Brain-Barrier Permeability (Log BB)	126
11	Solubility	128
12	Examples of the Use of Chemical Annotation and Pharmacophore-Based Lead-Hopping	129
13	Compound Acquisition	132
	Acknowledgments	134
	References	134
Chapter 6	Chemical Diversity: Definition and Quantification	137
	<i>Alan C. Gibbs and Dimitris K. Agrafiotis</i>	
1	Introduction	137

2	Diversity Metrics	138
2.1	Distance-Based Metrics	138
2.2	Cell-Base Diversity Metrics	140
2.3	Variance-Based Diversity Metrics	142
3	Molecular Description	143
3.1	Two-Dimensional Descriptors	143
3.2	Three-Dimensional Descriptors	145
3.3	Physicochemical and Electronic Descriptors	146
3.4	Descriptor Selection	146
4	Dimensionality Reduction	147
4.1	Principle Component Analysis	148
4.2	Singular-Value Decomposition	148
4.3	Factor Analysis (FA)	149
4.4	MultiDimensional Scaling	149
4.5	Stochastic Proximity Embedding	150
5	Subset Selection and Classification	151
5.1	Clustering	152
5.2	Partitioning Methods	153
5.3	Experimental Design	154
5.4	Reagent-Based Versus Product-Based Design	155
5.5	Random Versus Rational Design	155
6	Conclusion	156
	Abbreviations	156
	References	156

Section 3 Conceptual Advances in Synthesis: “Mining” – Turning a Hit into a Lead

Chapter 7	Focused Libraries: The Evolution in Strategy from Large-Diversity Libraries to the Focused Library Approach	163
	<i>Ruben Tommasi and Ivan Cornella</i>	
1	Introduction	163
2	A Synergistic, Multidisciplinary Approach to Library Conception	164
2.1	Improvements in Synthetic Methods	164
2.2	Impact of <i>In Silico</i> Tools for Library Design	165
2.3	Influence of Biology in Library Design	166
3	Library Design Concepts	167
3.1	Impact of Diversity on Library Design	167
3.2	Diversity-Oriented Synthesis in Prospecting Library Design	168
3.3	Target-Oriented Library Design	168
3.4	Focus on Drug-Like Libraries	170

4	Focused Libraries	170
4.1	Libraries Focused on Pharmacophore Models	170
4.2	Libraries Focused on Privileged Structures	172
4.3	Libraries Focused on Target Classes	172
4.3.1	GPCR-Targeted Libraries	173
4.3.2	Kinase-Targeted Libraries	174
4.3.3	Natural Product-Based Focused Libraries	174
4.4	Early Optimization or Hit-to-Lead Libraries	177
5	Summary	179
	References	179
Chapter 8	Translating Peptides into Small Molecules	184
	<i>Gerd Hummel, Ulrich Reineke and Ulf Reimer</i>	
1	Peptides as Drugs: The Good, the Bad and the Ugly	184
2	Origin of Biologically Active Peptides	185
3	General Strategy for Translating Peptides into Small Molecules	186
4	Tailoring Peptide Sequences for their Translation into Small Molecules	186
5	Transformation of Peptide Ligands into Small Molecules using Computational Approaches	191
6	Conclusion	198
	References	198
Section 4	Operational Developments in Screening and High Throughput Assays	
Chapter 9	High-Density Plates, Microarrays, Microfluidics	203
	<i>Christof Fattinger and Gregor Dernick</i>	
1	Functional High-Density Well Plates for High-Throughput Assays	204
1.1	Sample Plates for Low-Volume High-Throughput Screening	205
1.2	High-Density Assay Plates for HTS and Multidimensional Compound Profiling	206
1.3	Technical, Biological, and Economical Limits for Assay Miniaturization in High-Density Plates	208
1.4	384-Microtube Plate for High-Throughput Retrieval of Compound Subsets	210
1.5	Sample Management for HTS and Multidimensional Compound Profiling	211

2	Parallel Liquid Handling of Low-Volume Samples	215
2.1	Pipetting and Dispensing in High-Density Plates	215
2.2	High-Throughput Aliquoting of the HTS Library	219
2.3	A Microfluidic Well Plate for High-Throughput Solid/Liquid Separations	222
3	Microarray Assays on Chips	223
3.1	Microchannel Assay: A New Generation of Miniaturized Multiplexed Bioassays	226
4	Prospects for Multiparameter Assays	229
	Acknowledgment	231
	References	231
Chapter 10	Fluorescence Technologies for the Investigation of Chemical Libraries	233
	<i>Eric Trinquet and Gérard Mathis</i>	
1	Introduction	233
2	Dissociation-Enhanced Lanthanide Fluoroimmunoassay	234
3	Enzyme Fragment Complementation	236
4	Fluorescence Polarization	236
5	Fluorescence Correlation Spectroscopy	238
6	Amplified Luminescent Proximity Homogeneous Assay (AlphaScreen™)	238
7	Fluorescence Resonance Energy Transfer	239
8	Bioluminescence Resonance Energy Transfer	241
9	Homogeneous Time Resolved Fluorescence	241
10	Conclusion	244
	References	245
Chapter 11	The Use of Genetically Engineered Cell-Based Assays in <i>in-vitro</i> Drug Discovery	247
	<i>Renate Schnitzer and Wolfgang Sommergruber</i>	
1	Introduction	247
2	Genetic Engineering for Cell-Based Assays	248
2.1	Expression Systems	248
2.2	Choice of Cell Line and Promoter	249
2.3	Chromosomal Integration Site	250
3	Reporter-Based Assays	250
3.1	Chloramphenicol Acetyl Transferase, Secreted Placental Alkaline Phosphatase, β -Galactosidase	251

3.2	Green Fluorescent Protein	252
3.3	Luciferase	252
3.4	β -Lactamase	253
3.5	Examples of Applications	254
4	Assays to Measure Intracellular Calcium	256
5	Assays to Monitor Protein–Protein Interactions	257
5.1	Bioluminescence Resonance Energy Transfer and Fluorescence Resonance Energy Transfer	257
5.2	Enzyme Complementation	258
6	Conclusions and Outlook	259
	References	260
Chapter 12	NMR-Based Screening: A Powerful Tool in Fragment-Based Drug Discovery	263
	<i>Jochen Klages, Murray Coles and Horst Kessler</i>	
1	Introduction	263
2	NMR Screening: General Aspects	266
3	Ligand- vs. Target-Detected Methods	268
3.1	Sample Requirements	268
4	Incorporation of NMR into the Drug Discovery Process	269
4.1	Hit Finding	270
4.1.1	STD and WaterLOGSY	270
4.1.2	Libraries of ^{19}F -Containing Ligands	272
4.2	Hit Validation	273
4.2.1	Chemical Shift Mapping	273
4.3	Hit Optimization	274
4.3.1	Chemical Shift Mapping	274
4.3.2	Competition-Based Screening	275
4.3.3	Paramagnetic Spin Labels	276
5	Representative Case Studies	277
5.1	Fluorine Screening	277
5.2	SAR-by-NMR	282
5.3	Saturation Transfer Double Difference	285
6	Conclusion	287
	References	288
Chapter 13	Screening Chemical Microarrays: Methods and Applications	291
	<i>Pappanaicken R. Kumaresan and Kit S. Lam</i>	
1	Introduction	291
1.1	<i>In situ</i> Synthesis of Peptide and Non-Peptide Microarrays	293

1.2	Spotting of Pre-Synthesized Small Molecules and Peptides	293
1.3	Carbohydrate Microarrays	293
1.4	One-Bead-One-Compound Combinatorial Library Bead-Arrays	294
2	Screening of Chemical Microarrays	295
2.1	Labeling Methods	296
2.1.1	Fluorescence Method	296
2.1.2	Chemiluminescence Method	297
2.1.3	Radiolabeling Methods	297
2.1.4	Colorimetric Methods	297
2.2	Label-Free Optical and Mass Spectrometry Methods	298
2.2.1	Surface Plasmon Resonance	298
2.2.2	Oblique-Incidence Optical Reflectivity Difference Microscopy	298
2.2.3	Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry	298
2.2.4	Atomic Force Microscopy	299
2.2.5	Fiber-Optic Bead Methods	299
2.2.6	Laser-Detection Methods	299
2.2.7	Electrochemical Biosensor Method	299
2.2.8	Cell-Based Assays	300
3	Applications of Chemical Microarrays	300
3.1	Basic Science Applications	301
3.1.1	Protein-Binding Arrays	301
3.1.2	Carbohydrate Microarrays for Cell Receptors	302
3.1.3	Cell-Signaling Arrays	302
3.1.4	Enzyme Substrate/Inhibitor Arrays	303
3.1.5	Chemical-Detection Arrays	303
3.2	Medical Applications	304
3.2.1	Diagnostic Arrays	304
3.2.2	Immunological Arrays	304
3.2.3	Cell-Binding Arrays	305
3.2.4	Drug-Discovery Arrays	305
4	Conclusion	306
	Acknowledgments	306
	References	307

Section 5 Conceptual Advances in Lead Evaluation: Screen Early and Often

Chapter 14	Screen/Counter-Screen: Early Assessment of Selectivity	315
	<i>Martyn N. Banks, Litao Zhang and John G. Houston</i>	
1	Introduction	315
2	Approaches Used for Selection of Drug Candidates	317
2.1	Lead Evaluation and Liability Profiling	317
2.1.1	ADME Liability Profiling	318
2.1.2	The Lead Evaluation Process: Technologies and Methods	319
2.2	Specificity of Drug Candidates and the Construction of <i>In Vitro</i> Specificity Panels	323
2.2.1	Receptors	323
2.2.2	Protein Kinases	328
2.2.3	Ion Channels	331
3	Summary	332
	References	332
Chapter 15	Concepts for <i>In Vitro</i> Profiling: Drug Activity, Selectivity and Liability	336
	<i>Michael B. Bolger, Robert Fraczkiwicz, Michael Entzeroth and Boyd Steere</i>	
1	Introduction	336
2	Physicochemical Parameters	339
2.1	Partition Coefficient	339
2.2	pK _a	340
2.3	Solubility	343
2.3.1	Thermodynamic Solubility	343
2.3.2	To Buffer or not to Buffer	345
3	Permeability	348
4	Metabolism	350
5	Protein Binding	353
6	Toxicity	354
6.1	Cell Viability: MTS Assay for <i>In Vitro</i> Cytotoxicity	355
6.2	Membrane Damage: Release of LDH (Lactate Dehydrogenase)	355
6.3	Induction of Apoptosis: Caspase Activity	355
6.4	HERG Potassium Channel Interaction	355

6.5	Microarrays	356
6.6	Recent Approaches	357
7	Investigation of Compound Selectivity	357
8	Conclusion and Outlook	357
	References	360
Chapter 16	<i>In Silico</i> Surrogates for <i>In Vivo</i> Properties: Profiling for ADME and Toxicological Behavior	364
	<i>Michael B. Bolger, Robert Fraczekiewicz and Boyd Steere</i>	
1	<i>In Silico</i> Surrogates for <i>In Vivo</i> Properties	364
1.1	Molecular Descriptor Generation	365
1.2	Modeling Methods	366
1.3	Multiple Linear Regression	366
1.4	Partial Least Squares	367
1.5	Artificial Neural Network	367
1.6	Support Vector Machines	368
2	Estimation of Biopharmaceutical Properties	369
2.1	Partition Coefficient	369
2.2	pK _a	369
2.3	Permeability	374
2.4	Solubility	374
2.5	Protein Binding	376
3	Estimation of Pharmacokinetic Properties	377
3.1	Clearance	377
3.2	Volume of Distribution	377
3.3	Metabolism	378
4	Estimation of Toxicological Properties	379
5	Integration of Surrogate Data and Estimations with Physiological Simulation	380
	References	381
Chapter 17	Uses of High Content Screening in Chemical Optimization	386
	<i>Francesca Casano, Zhuyin Li and Tina Garyantes</i>	
1	Introduction	386
2	When is HCS Used	387
3	HCS Systems	388
3.1	Limitations of HCS	388
3.2	How to Pick an HCS System	389

4	Examples Show the Power of HCS	390
4.1	Example 1: NF- κ B Nuclear Translocation Assay (from Prelux)	390
4.2	Example 2: Characterization of Apoptosis Pathways Using High-Throughput Image-Based Assays (from Prelux)	394
4.3	Example 3: Gap Junction Inhibitors (from sanofi-aventis)	400
5	Summary	402
	References	404
	Subject Index	405